Search Thermo Fisher Scientific
Disclaimer
Clicking the images or links will redirect you to a website hosted by BenchSci that provides third-party scientific content. Neither the content nor the BenchSci technology and processes for selection have been evaluated by us; we are providing them as-is and without warranty of any kind, including for use or application of the Thermo Fisher Scientific products presented.
Invitrogen
Romosozumab Humanized Recombinant Human Monoclonal Antibody
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promotions']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.viewpromo']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promocode']}}: {{promo.promoCode}} {{promo.promoTitle}} {{promo.promoDescription}}. {{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.learnmore']}}
Product Details
MA5-41957
Product Specifications
Species Reactivity
Human
Host/Isotype
Human
/ IgG2, kappa
Expression System
CHO cells
Class
Recombinant Monoclonal
Type
Antibody
Immunogen
Human SOST
Conjugate
Form
Liquid
Concentration
3.33 mg/mL
Purification
Protein A
Storage buffer
PBS, pH 7.5
Contains
no preservative
Storage conditions
-20°C, Avoid Freeze/Thaw Cycles
Shipping conditions
Ambient (domestic); Wet ice (international)
RRID
AB_2911100
Product Specific Information
Endotoxin level < 0.01EU/µg by LAL method
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 °C for one week. Store at -20 to -80 °C for twelve months from the date of receipt.
Target Information
Romosozumab is a humanized monoclonal antibody indicated for the treatment of osteoporosis in postmenopausal women at high risk of fracture and patients who have failed in other treatments or are intolerant to other osteoporosis therapies9. Romosozumab prevents bone resorption and induces the formation of bone though it is associated with an increased risk of cardiac death, heart attack, and stroke in one study7, 8. In a comparison study of post menopausal women with osteoporosis and a past fracture, romosozumab for 12 months followed by alendronic acid for 12 months was superior to alendronic acid alone for 24 months3. Romosozumab also demonstrates a faster and larger increase in bone density than teriparatide4. Romosozumab is marketed in the United States by Amgen under the brand name Evinity7. Romosozumab was granted FDA approval on April 9, 2019.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
References (0)
Have you cited this product in a publication?
Let us know so we can reference it here.
Performance Guarantee
If an Invitrogen™ antibody doesn't perform as described on our website or datasheet,we'll replace the product at no cost to you, or provide you with a credit for a future purchase.*
Learn more
We're here to help
Get expert recommendations for common problems or connect directly with an on staff expert for technical assistance related to applications, equipment and general product use.
Contact tech support